Results 101 to 110 of about 4,071 (233)

Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis

American Journal of Ophthalmology Case Reports, 2020
To report a case of intravitreal methotrexate treatment and fluocinolone acetonide (Retisert®) implantation in a patient with Vogt-Koyanagi-Harada syndrome (VKH).A 34-year-old male was referred for worsening vision and bilateral panuveitis consistent with VKH.
Jong G. Park, Natalia F. Callaway, Cassie A. Ludwig, Vinit B. Mahajan   +3 more
openaire   +3 more sources

Integrating Computational and Biological Hemodynamic Approaches to Improve Modeling of Atherosclerotic Arteries

Advanced Science, Volume 11, Issue 26, July 10, 2024.
This review describes and critically evaluates computational and biological models of atherosclerosis, focusing on the hemodynamics of occluded coronary arteries. It examines emerging strategies that integrate computational and biological models and explores the advances in imaging, biofabrication, single‐cell omics, and machine learning for model ...
Thao Nhu Anne Marie Vuong, Michael Bartolf‐Kopp, Kristina Andelovic, Tomasz Jungst, Nona Farbehi, Steven G. Wise, Christopher Hayward, Michael Charles Stevens, Jelena Rnjak‐Kovacina   +8 more
wiley   +1 more source

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review

Ophthalmology and Therapy, 2018
Diabetic macular edema (DMO) is a leading cause of blindness in the working age population. Although anti-vascular endothelial growth factor (VEGF) therapy provided a major advance in treatment of DMO for many patients, there is a significant proportion ...
William Fusi-Rubiano, Rebecca R. Blow, Mark Lane, Rupal Morjaria, Alastair K. Denniston   +4 more
doaj   +1 more source

Treatment of Posterior Uveitis With a Fluocinolone Acetonide Implant [PDF]

Archives of Ophthalmology, 2008
To evaluate the safety and efficacy of 0.59-mg and 2.1-mg fluocinolone acetonide (FA) intravitreous implants in noninfectious posterior uveitis.A 3-year, multicenter, randomized, historically controlled trial of the 0.59-mg FA intravitreous implant in 110 patients and the 2.1-mg FA intravitreous implant in 168 patients.Recurrence rate, vision, and ...
David G, Callanan, Glenn J, Jaffe, Daniel F, Martin, P Andrew, Pearson, Timothy L, Comstock   +4 more
openaire   +2 more sources

Cost‐Effectiveness of Topical Prophylaxis Against Tympanostomy Tube Otorrhea: An Economic Decision Analysis

OTO Open, Volume 8, Issue 3, July–September 2024.
Abstract Objective To evaluate the cost‐effectiveness of various topical prophylaxis strategies against posttympanostomy otorrhea using a break‐even analysis. Study Design An economic decision analysis of data collected from purchasing records and the literature. Setting An academic center.
Grant Conner, Yuki Yoshiyasu, Nicholas Rossi, Brian McKinnon   +3 more
wiley   +1 more source

Ophtalmologie. Rétinopathie diabétique: nouvelles possibilités thérapeutiques [Diabetic retinopathy: new therapeutic possibilities]. [PDF]

, 2015
La rétinopathie diabétique touche un nombre croissant de personnes, soit quatre millions en Europe, ce chiffre va probablement doubler d'ici 2030. Si l'on considère que 25-30% de ces patients sont atteints de rétinopathie diabétique, un dépistage et un ...
Behar-Cohen, F., Guex-Crosier, Y.
core  

Use of flucinolone acetonide for patients with diabetic macular oedema:patient selection criteria and early outcomes in real world setting [PDF]

, 2016
Introduction: Fluocinolone acetonide slow release implant (Iluvien®) was approved in December 2013 in UK for treatment of eyes which are pseudophakic with DMO that is unresponsive to other available therapies.
Ajay Bhatnagar, Andrej Kidess, CS Brand, D Boyer, DM Brown, DS Boyer, DS Levin, E Chew, Fahad Quhill, Ibrahim Elaraoud, JA Wells, JW Yau, Marie Tsaloumas, MJ Elman, NZ Gregori, PA Campochiaro, PA1 Campochiaro, Walter Andreatta, Yit Yang   +18 more
core   +1 more source

A review on polymers in ocular drug delivery systems

MedComm – Biomaterials and Applications, Volume 3, Issue 2, June 2024.
Polymers play a pivotal role in ocular drug delivery, revolutionizing treatment approaches. These biomaterials enable controlled and sustained drug release at the targeted site, enhancing bioavailability and patient compliance. From nanosized particle‐based formulations to in situ gelation mechanisms, polymers offer improved treatment options for a ...
Amol C. Bisen, Arpon Biswas, Ayush Dubey, Sachin N. Sanap, Sristi Agrawal, Karan S. Yadav, Vaishali Singh, Priyanka Rawat, Sudhanshu Sagar, Madhav N. Mugale, Rabi S. Bhatta   +10 more
wiley   +1 more source

Scleral melt following Retisert intravitreal fluocinolone implant

Drug Design, Development and Therapy, 2014
Ilias Georgalas,1 Chrysanthi Koutsandrea,1 Dimitrios Papaconstantinou,1 Dimitrios Mpouritis,1 Petros Petrou1,2 1Ophthalmology Department, University of Athens, Athens, Greece; 2Moorfields Eye Hospital, London, UKAbstract: Intravitreal fluocinolone ...
Georgalas I, Koutsandrea C, Papaconstantinou D, Mpouritis D, Petrou P   +4 more
doaj  

Drug Delivery Innovation during Cataract Surgery: Are We Ready for Dropless Cataract Surgery?

Delhi Journal of Ophthalmology, 2019
At present, drug administration options during cataract surgery include topical application. Subconjunctival application is not used now. Intracameral Injection is reserved for antibiotic supplement.
Suresh K. Pandey, Vidushi Sharma
doaj   +1 more source